Suchergebnisse - "Parassol, Nadège"

PubPharm (20)

1

Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events : a case-control study

enthalten in: Clinical kidney journal | 2022

von Gérard, A. | Barbosa, S. | Parassol, N. | +12

2

Case Report : Severe Hypercalcemia Following Vitamin D Intoxication in an Infant, the Underestimated Danger of Dietary Supplements

enthalten in: Frontiers in pediatrics | 2022

von Gérard, A. | Fresse, A. | Gast, M. | +8

3

Immune checkpoint inhibitors-induced nephropathy : a French national survey

enthalten in: Cancer immunology, immunotherapy : CII | 2021

von Gérard, A. | Andreani, M. | Fresse, A. | +9

4

Immune checkpoint inhibitors-induced nephropathy: a French national survey

enthalten in: Cancer immunology immunotherapy | 2021

von Gérard, A. | Andreani, M. | Fresse, A. | +8

5

Immune checkpoint inhibitors-induced nephropathy: a French national survey

enthalten in: Cancer immunology immunotherapy | 2021

von Gérard, A. | Andreani, M. | Fresse, A. | +8

6

Immune checkpoint inhibitors-induced nephropathy: a French national survey

enthalten in: Cancer immunology immunotherapy | 2021

von Gérard, A. | Andreani, M. | Fresse, A. | +8

7

Remdesivir and Acute Renal Failure : A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

enthalten in: Clinical pharmacology and therapeutics | 2021

von Gérard, A. | Laurain, A. | Fresse, A. | +5

ErratumIn: Clin Pharmacol Ther. 2022 Jun;111(6):1343. - PMID 35385584

8

Remdesivir and Acute Renal Failure : A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

enthalten in: Clinical Pharmacology & Therapeutics | 2021

von Gérard, A. | Laurain, A. | Fresse, A. | +5

9

Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio

enthalten in: Journal of cardiovascular pharmacology | 2020

von Bernier, M. | Lancrerot, S. | Parassol, N. | +4

CommentIn: J Cardiovasc Pharmacol. 2020 Oct;76(4):374-375. - PMID 33027194

10

"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19 : A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

enthalten in: Therapie | 2020

von Gérard, A. | Romani, S. | Fresse, A. | +7